已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: Primary results from PALOMA-4

帕博西利布 来曲唑 医学 人表皮生长因子受体2 内科学 乳腺癌 安慰剂 肿瘤科 绝经后妇女 转移性乳腺癌 雌激素受体 妇科 癌症 雌激素受体 三苯氧胺 替代医学 病理
作者
Binghe Xu,Xichun Hu,Wěi Li,Tao Sun,Kunwei Shen,Shusen Wang,Ying Cheng,Qingyuan Zhang,Shude Cui,Zhongsheng Tong,Cuizhi Geng,Erwei Song,Chiun‐Sheng Huang,Virote Sriuranpong,Roger K.C. Ngan,Yee Hong Chia,Xinwei Wang,Huadong Zhao
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:175: 236-245 被引量:46
标识
DOI:10.1016/j.ejca.2022.08.012
摘要

BackgroundThe cyclin-dependent kinase 4/6 inhibitor palbociclib has demonstrated efficacy and a manageable safety profile in combination with endocrine therapy in women with oestrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC) in international phase 3 trials. The phase 3 PALOMA-4 trial evaluated the efficacy and safety of palbociclib plus letrozole versus placebo plus letrozole in Asian women with ER+/HER2– ABC.MethodsPostmenopausal women (n = 340) with no prior systemic treatment for advanced disease were randomised 1:1 to palbociclib (125 mg/d orally; 3 weeks on, 1 week off) plus letrozole (2.5 mg/d orally; continuously) or placebo plus letrozole. The primary end-point was investigator-assessed progression-free survival (PFS). Secondary end-points included tumour response and safety.ResultsMedian (95% CI) PFS was 21.5 (16.6–24.9) months with palbociclib plus letrozole and 13.9 (13.7–16.6) months with placebo plus letrozole (hazard ratio, 0.68 [95% CI, 0.53–0.87]; P = 0.0012). Consistent with the established safety profile, the most common adverse events (AEs) with palbociclib plus letrozole were neutropenia, leukopenia, thrombocytopaenia, and anaemia. Grade 3/4 neutropenia was reported in 84.5% of patients in the palbociclib arm versus 1.2% in the placebo arm. One serious AE of febrile neutropenia in the palbociclib group was reported.ConclusionsFindings from PALOMA-4 support the efficacy and safety of first-line palbociclib plus letrozole in postmenopausal Asian women with ER+/HER2– ABC. No new safety concerns of palbociclib plus letrozole were identified.Trial registrationClinicaltrials. gov, NCT02297438.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Rain完成签到,获得积分10
1秒前
李健应助罗布林卡采纳,获得80
1秒前
星瑗完成签到 ,获得积分10
1秒前
优雅的半梅完成签到 ,获得积分10
2秒前
香蕉觅云应助关天木采纳,获得10
3秒前
Chen发布了新的文献求助30
5秒前
6秒前
想吃桔子完成签到,获得积分10
7秒前
关天木完成签到,获得积分10
8秒前
9秒前
9秒前
nicezhutou完成签到 ,获得积分10
10秒前
12秒前
13秒前
科研通AI2S应助yy123采纳,获得10
13秒前
关天木发布了新的文献求助10
15秒前
华仔应助Chen采纳,获得30
17秒前
HEIKU应助xiaoxiao采纳,获得10
19秒前
李键刚完成签到 ,获得积分10
24秒前
DR.V完成签到,获得积分10
24秒前
31秒前
31秒前
sarah完成签到,获得积分10
32秒前
33秒前
33秒前
初夏完成签到,获得积分10
34秒前
脑洞疼应助二橦采纳,获得30
35秒前
35秒前
万灵竹发布了新的文献求助10
37秒前
dennisysz发布了新的文献求助10
37秒前
小杨发布了新的文献求助10
37秒前
动漫大师发布了新的文献求助10
38秒前
CGBIO发布了新的文献求助10
42秒前
h888完成签到,获得积分20
43秒前
Lucas应助小杨采纳,获得10
45秒前
隐形曼青应助科研通管家采纳,获得10
45秒前
科研通AI5应助科研通管家采纳,获得10
45秒前
所所应助科研通管家采纳,获得10
45秒前
桐桐应助科研通管家采纳,获得10
45秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
ISCN 2024 – An International System for Human Cytogenomic Nomenclature (2024) 3000
Continuum Thermodynamics and Material Modelling 2000
Encyclopedia of Geology (2nd Edition) 2000
105th Edition CRC Handbook of Chemistry and Physics 1600
Maneuvering of a Damaged Navy Combatant 650
the MD Anderson Surgical Oncology Manual, Seventh Edition 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3777470
求助须知:如何正确求助?哪些是违规求助? 3322842
关于积分的说明 10212001
捐赠科研通 3038215
什么是DOI,文献DOI怎么找? 1667213
邀请新用户注册赠送积分活动 798010
科研通“疑难数据库(出版商)”最低求助积分说明 758147